Answer
Immunoglobulin levels are monitored during Elrexfio (elranatamab) treatment because hypogammaglobulinaemia has been reported, and subcutaneous or intravenous immunoglobulin treatment should be considered if IgG falls below 400 mg/dL.
Sources for this answer
- ELREXFIO 40 mg/mL solution for injectionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked